IL-2 produced by HBV-specific T cells as a biomarker of viral control and predictor of response to PD-1 therapy across clinical phases of chronic hepatitis B.

Hepatol Commun · 2023 · PMC10984660 · PMID 38055623

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

approached significanceno p-value reported

In contrast to HBV-specific IFN-γ+ responses that did not differ significantly between phases (Figure 1 B), HBV-specific (background subtracted) IL-2+ SFU were significantly higher in IC compared to IA+ patients ( p =0.0185) and approached significance between IC and IT patients (Figure 1 E).

also in 8,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.